$7.38—Stale · unknown old
NASDAQ • Last print unknown ago
$7.38—Stale · unknown old
Kelly CRISPR & Gene Editing Technology ETF (XDNA) focuses on investments in companies engaged in CRISPR and gene editing technologies, primarily in North America and Europe. The ETF targets firms with proprietary technologies and strong intellectual property portfolios, which provide a competitive edge in the rapidly evolving biotech landscape.
XDNA generates revenue through management fees based on the total assets under management, which are derived from investments in high-growth biotech companies specializing in gene editing. The ETF's competitive advantage lies in its focus on cutting-edge technologies and a diversified portfolio that mitigates risks associated with individual biotech stocks.
Advancements in CRISPR technology and regulatory approvals for gene therapies
Market sentiment towards biotech sector performance
Changes in investor appetite for high-growth, high-risk assets
M&A activity within the biotech space
Regulatory changes affecting gene editing technologies
Technological disruption from emerging biotech innovations
Increased competition from other biotech-focused ETFs
Potential for rapid advancements in alternative gene editing technologies
Market volatility impacting AUM and management fee revenue
Liquidity risks associated with biotech investments
moderate - The biotech sector can be sensitive to economic cycles, as funding and investment in high-risk technologies may decline during economic downturns.
Higher interest rates can increase the cost of capital for biotech firms, potentially dampening innovation and investment in the sector, which may negatively impact ETF performance.
minimal - The ETF does not have significant credit exposure as it primarily invests in equities.
growth - Investors seeking exposure to high-growth biotech innovations and willing to accept higher volatility.
high - The ETF is likely to exhibit high volatility due to the nature of its underlying investments.